Breaking Barriers: The Promise and Challenges of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is a highly aggressive malignancy with pronounced immunogenicity, exhibiting rapid proliferation and immune cell infiltration into the tumor microenvironment. TNBC’s heterogeneity poses challenges to immunological treatments, inducing resistance mechanisms in the...
Main Authors: | Sawsan Sudqi Said, Wisam Nabeel Ibrahim |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-02-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/12/2/369 |
Similar Items
-
Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer
by: Ji-Yeon Kim, et al.
Published: (2023-03-01) -
Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma
by: Lijun Peng, et al.
Published: (2022-09-01) -
Immune Checkpoint Inhibitors in Cancer Therapy
by: Yavar Shiravand, et al.
Published: (2022-04-01) -
Immunotherapy using PD‑1/PDL-1 inhibitors in triple‑negative breast cancer: a systematic review
by: Dione Tavares, et al.
Published: (2021-12-01) -
The Role of Immune Checkpoint Inhibitors in Cancer Therapy
by: Ahmed M. Basudan
Published: (2022-12-01)